Navigation Links
Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes

diet and exercise, to improve glycemic control in adult patients with type 2 diabetes who are not adequately controlled on metformin or sitagliptin alone or in patients already being treated with the combination of sitagliptin and metformin. Consistent with the labeling for metformin alone, JANUMET is contraindicated in patients with renal disease, renal dysfunction, or abnormal creatinine clearance; and acute or chronic metabolic acidosis, including diabetic ketoacidosis. JANUMET should not be used in patients with type 1 diabetes. Consistent with the labeling for metformin alone, the labeling for JANUMET contains a boxed warning for lactic acidosis, a rare, but serious, metabolic complication that can occur due to metformin accumulation during treatment with JANUMET.

Initial combination therapy with JANUVIA and metformin significantly improved blood sugar control compared with metformin alone over one year (LB-04; Study #036)

This study demonstrated a mean A1C reduction from baseline of 1.8 percent in patients treated with JANUVIA 50 mg/metformin 1000 mg twice daily for up to 54 weeks (n=153). Additionally, mean A1C reductions from baseline were 1.4 percent in patients treated with JANUVIA 50 mg/metformin 500 mg twice daily (n=147), 1.3 percent in patients treated with metformin 1000 mg twice daily (n=134), 1.0 percent in patients treated with metformin 500 mg twice daily (n=117), and 0.8 percent in patients treated with JANUVIA 100 mg once daily (n=106).

After completing an initial 24-week placebo-controlled phase (n=1091) ("Phase A"), 762 patients with a mean baseline A1C of 8.7 percent continued in a 30-week, double-blind, active-controlled phase ("Phase B") on their previous active treatments: JANUVIA 50 mg/metformin 1000 mg twice daily (n=161); JANUVIA 50 mg/metformin 500 mg twice daily (n=160); metformin 1000 mg twice daily (n=153); metformin 500 mg twice daily (n=147); and JANUVIA 100 mg once-daily (n=141).

Two-thirds (67 percent
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
2. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
5. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
6. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
7. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
8. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
9. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
10. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
(Date:8/26/2014)... DIEGO , Aug. 26, 2014 Profil ... research organization (CRO) focused on diabetes and obesity, announced ... completion of more than 200 phase I – IIa ... the treatment of type 1 and type 2 diabetes. ... of research is what it represents for the public ...
(Date:8/26/2014)... , Aug. 26, 2014  Ruthigen Inc. (NASDAQ: ... on improving patient outcomes and reducing healthcare costs ... drug candidate, RUT58-60, has received a recommendation from ... patients in the Company,s planned Phase 1/2 clinical ... as an adjunct therapy in combination with prophylactic ...
(Date:8/26/2014)...   Organovo Holdings, Inc. (NYSE MKT: ONVO) ... 3D bioprinting technology, announced today that it has been recognized ... World Economic Forum (WEF) .  Organovo is one ... creativity to design and create transformative solutions. ... Pioneer by the World Economic Forum for the innovation ...
Breaking Medicine Technology:Profil Institute Reaches Milestone in Early Phase Clinical Research for Diabetes 2Profil Institute Reaches Milestone in Early Phase Clinical Research for Diabetes 3Ruthigen Receives Recommendation from Data Monitoring Committee to Initiate Phase 1/2 Human Clinical Trial of RUT58-60 2Ruthigen Receives Recommendation from Data Monitoring Committee to Initiate Phase 1/2 Human Clinical Trial of RUT58-60 3Ruthigen Receives Recommendation from Data Monitoring Committee to Initiate Phase 1/2 Human Clinical Trial of RUT58-60 4Organovo Named 2015 Technology Pioneer by World Economic Forum 2Organovo Named 2015 Technology Pioneer by World Economic Forum 3
... Primary Endpoint, with Positive Effect Sustained Through ... Duration of 4-Week ... VNDA ) (Vanda) today announced positive top-line results from,a Phase III ... agonist, met the primary endpoint,of the trial and significantly improved sleep ...
... with initiatives aimed at knowledge transfer, including landmark ... Massachusetts and the Italian government in ... an innovator and,leader in global patient recruitment for clinical ... of initiatives to make its,quarter-century of expertise more accessible ...
Cached Medicine Technology:Phase III Data Show Vanda Pharmaceuticals' Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia 2Phase III Data Show Vanda Pharmaceuticals' Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia 3Phase III Data Show Vanda Pharmaceuticals' Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia 4Phase III Data Show Vanda Pharmaceuticals' Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia 5Phase III Data Show Vanda Pharmaceuticals' Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia 6Phase III Data Show Vanda Pharmaceuticals' Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia 7Phase III Data Show Vanda Pharmaceuticals' Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia 8Phase III Data Show Vanda Pharmaceuticals' Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia 9BBK Worldwide Celebrates 25th Anniversary of Industry Leadership Through Innovation in Patient Enrollment 2BBK Worldwide Celebrates 25th Anniversary of Industry Leadership Through Innovation in Patient Enrollment 3BBK Worldwide Celebrates 25th Anniversary of Industry Leadership Through Innovation in Patient Enrollment 4
(Date:8/27/2014)... Georgia (PRWEB) August 27, 2014 ... of PartnerTech AB, a major systems integration and ... Impact Cryotherapy offering the first U.S. designed ... Inc. offered the ideal combination of manufacturing expertise, ... cryotherapy system. Impact Cryotherapy, headquartered in Atlanta, GA, ...
(Date:8/26/2014)... Hearing aids are not always ... plan holders to determine what their hearing care benefits are. ... additional health plans and has published benefit details on their ... , The following is a list of insurances or ... , NYSHIP/ NYS Empire Plan - Hearing Aid Benefit is ...
(Date:8/26/2014)... (PRWEB) August 27, 2014 Leelanau ... a fabulous time to visit the region’s wineries. Rolling ... backdrop to wine tasting fun in a weekend event ... Kicking off the festivities is an optional race through ... Vineyards in Suttons Bay. A unique course between rows ...
(Date:8/26/2014)... (PRWEB) August 26, 2014 The ... recipients of the Bruce Simpson Winemaker Scholarship. The ... recipients will each receive $1,000 for the 2014/2015 ... Stemo, Alexis Bogdanova-Hanna and Ashley Nitz. , The ... careers as winemakers and vineyardists in northern Michigan. ...
(Date:8/26/2014)... Charles, LA (PRWEB) August 27, 2014 ... irreversible, it simply makes sense to use hearing ... risk losing hearing forever. There are many different ... and recreational use. Employers generally provide hearing protection ... law enforcement, and other noisy industries. The National ...
Breaking Medicine News(10 mins):Health News:PartnerTech Inc. and Impact Cryotherapy Announce Made in America Manufacturing Initiative 2Health News:PartnerTech Inc. and Impact Cryotherapy Announce Made in America Manufacturing Initiative 3Health News:East End Hearing of Long Island Now Participating in Many Local Health Plans 2Health News:East End Hearing of Long Island Now Participating in Many Local Health Plans 3Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers One-of-a-Kind Walk or Run Through the Vineyards for Walkers, Runners and Wine Tasting Spectators Alike 2Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers One-of-a-Kind Walk or Run Through the Vineyards for Walkers, Runners and Wine Tasting Spectators Alike 3Health News:The Leelanau Peninsula Vintners Association (LPVA) Awards Its First-ever Bruce Simpson Winemakers Scholarships 2Health News:The Hearing Center of Lake Charles Adds a Complete Line of Occupational Hearing Protection Products and Services to Its Offerings 2Health News:The Hearing Center of Lake Charles Adds a Complete Line of Occupational Hearing Protection Products and Services to Its Offerings 3
... N.C. The addition of a chemotherapeutic drug for leukemia ... to enhance the response of certain ovarian cancers to treatment, ... Duke Comprehensive Cancer Center. , "We know that a ... types of cancers, including some ovarian cancers," said Deanna Teoh, ...
... 18 "Getting closer to controlling cancer" requires funding ... of the new federal stimulus, say former White House ... Washington University Medical Center breast cancer laboratory director, ... Denver Post. Weiner, Berg, and former government analyst Paulette ...
... Awareness Month , , SATURDAY, April 18 (HealthDay News) -- ... 200 sites across the United States in May, which ... and children with symptoms such as wheezing, coughing and ... the screenings that will be conducted by allergists. , ...
... (Nasdaq: ISTA ), today announced it will release first ... a conference call to discuss these results and provide a pipeline ... Date: Thursday, May 7, 2009, Time: 5:00 ... Internet: www.istavision.com, Domestic dial-in: 866-356-3377, ...
... PTU can cause liver disease, experts say , , FRIDAY, April ... of the antithyroid drug (PTU) in children has been endorsed ... editor in the April 9 New England Journal of ... liver disease in children and should no longer be used ...
... Perspective HARRISBURG, Pa., April 17 Agriculture ... the first meeting of the Governor,s Food Safety Council on ... The council will meet from 1 p.m. to 4 p.m. ... Harrisburg Area Community College . The council will hear a ...
Cached Medicine News:Health News:Addition of dasatinib to standard chemo cocktail may enhance effect in certain ovarian cancers 2Health News:Getting Closer to Controlling Cancer Requires Funding More Laboratories and Commitment Beyond Two Years of New Stimulus, Weiner and Berg Assert in Denver Post Oped 2Health News:Group Urges Public to Take Free Asthma Tests in May 2Health News:Drug May Be Dangerous for Kids With Graves' Disease 2Health News:Pennsylvania Governor's Food Safety Council to Hold First Meeting on April 22 2
Determination of Prothrombin Time (PT)by STA Analyzers (ISI~1.8).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
The CA method used on the Dade Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of calcium in serum....
The PHOS method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of phosphorus in serum....
For the quantitative in vitro determination of Magnesium in serum, plasma and urine...
Medicine Products: